PHRI :: Karl Drlica, Ph.D.

   Yuri Bushkin, Ph.D.
   Neeraj Chauhan, Ph.D.
   Loren Day, Ph.D.
   Karl Drlica, Ph.D.
   David Dubnau, Ph.D.
   Marila Gennaro, M.D.
   Gilla Kaplan, Ph.D.
   Fred Kramer, Ph.D.
   Barry Kreiswirth, Ph.D.
   Leonard Mindich, Ph.D.
   Arkady Mustaev, Ph.D.
   Harvey Penefsky, Ph.D.
   David Perlin, Ph.D.
   Richard Pine, Ph.D.
   Abraham Pinter, Ph.D.
   Issar Smith, Ph.D.
   Patricia Soteropoulos, Ph.D.
   Sanjay Tyagi, Ph.D.
   David Wah, Ph.D.
   Chaoyang Xue, Ph.D.

   Research Faculty
   Eugenie Dubnau, Ph.D.
   Patricia Fontán, Ph.D.
   Jeanette Hahn, Ph.D.
   Salvatore Marras, Ph.D.
   Marcela Rodriguez, Ph.D.
   Lisa K. Ryan, Ph.D.
   Xilin Zhao, Ph.D.

Karl Drlica, Ph.D.
	Recent Articles Shopsin B, Zhao X, Kreiswirth BN, Tillotson GS, Drlica K. (2004). *Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus?* Int J Antimicrob Agents. 2004 Jul;24(1):32-4 PMID: 15225857 The use of quinolones in the treatment of non-serious community-acquired methicillin-resistant Staphylococcus aureus is discussed. The new C8-modified quinolones may be suitable for such treatment but controlled trials should be carried out to ensure that the pharmacokinetics are such that there is little risk of resistance developing.

Copyright © 2010 All rights reserved.